- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01543100
Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal Gammopathy (PACMoG)
Study Overview
Status
Intervention / Treatment
Detailed Description
Principal objective : Research of a correlation of blood CEC and MPs with the tumoral volume and the clinico-biological staging of monoclonal gammopathies.
Secondary objectives : Research of a correlation of bone marrow endothelial cells and MPs, both measured by flow cytometry, with the tumoral volume and the clinico-biological staging of monoclonal gammopathies.
Principal analyses : Blood levels of CEC and its progenitors, soluble parameters of angiogenesis and of coagulability, and microparticles versus classical indicators of tumoral growth of monoclonal gammopathies (beta2-microglobulin and Ig peak).
Secondary analyses : Bone marrow levels of endothelial cells and its progenitors, soluble parameters of angiogenesis and of coagulability, and microparticles versus classical indicators of tumoral growth of monoclonal gammopathies (beta2-microglobulin and Ig peak).
Methodology : PACMoG is an interventional, prospective and multicentric pilot study. Biologic parameters will be determined at the diagnosis of monoclonal gammopathy. Results will be compared to the monoclonal gammopathy international staging and the clinical follow-up.
Procedures : Specific tests of the study will be realized from :
- Blood samples: 2 EDTA tubes and 1 tube without anticoagulant per included patient.
- Bone marrow: 3 ml collected during of myelogram punction made for the diagnosis.
In all cases, no additional sampling will be performed.
Specific analyses :
- Specific biological assays in blood and bone marrow will be:
- Endothelial and progenitor cells levels
- Number and cellular origin of MPSs
- Levels of phospholipid-dependant coagulability
- Soluble parameters of angiogenesis (VEGF, soluble CD146, endostatin)
- Soluble parameters of coagulability (Levels of thrombomodulin, tissue factor and D-Dimer)
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Bretagne
-
Rennes, Bretagne, France, 35033
- Rennes University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with monoclonal gammopathy either MGUS or myeloma at diagnosis or more than 3 months after a first myeloma treatment with chemotherapy and/or antiangiogenic drugs.
- Patient's age ≥ 18 years old,
- Patients having signed the specific consent of the study.
Exclusion Criteria:
- Treatment with chemotherapy and/or antiangiogenic drugs at the inclusion
- Age < 18 years old
- No specific consent of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: monoclonal gamopathy
Patients with monoclonal gammopathy either MGUS or myeloma at diagnosis or more than 3 months after a first myeloma treatment with chemotherapy and/or antiangiogenic drugs.
|
Specific tests of the study will be realized from :
In all cases, no additional sampling will be performed. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood levels of CEC and its progenitors
Time Frame: Day 1
|
Blood levels of CEC and its progenitors
|
Day 1
|
Blood levels of soluble parameters of angiogenesis and of coagulability
Time Frame: Day 1
|
Blood levels of soluble parameters of angiogenesis and of coagulability
|
Day 1
|
Blood levels of microparticles versus classical indicators of tumoral growth of monoclonal gammopathies (beta2-microglobulin and Ig peak).
Time Frame: Day 1
|
Blood levels of microparticles versus classical indicators of tumoral growth of monoclonal gammopathies (beta2-microglobulin and Ig peak).
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bone marrow levels of endothelial cells and its progenitors
Time Frame: Day 1
|
Bone marrow levels of endothelial cells and its progenitors
|
Day 1
|
Bone Marrow levels of soluble parameters of angiogenesis and of coagulability
Time Frame: Day 1
|
Bone Marrow levels of soluble parameters of angiogenesis and of coagulability
|
Day 1
|
Bone Marrow levels of microparticles versus classical indicators of tumoral growth of monoclonal gamopathies (beta2-mcicroglobulin and Ig peak).
Time Frame: Day 1
|
Bone Marrow levels of microparticles versus classical indicators of tumoral growth of monoclonal gamopathies (beta2-mcicroglobulin and Ig peak).
|
Day 1
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Benoît GUILLET, MD, Rennes University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LOC/10-02 - PACMoG
- 2010-A00378-31 (Other Identifier: ID RCB)
- B100413-10 (Other Identifier: AFSSAPS)
- 10/16-758 (Other Identifier: CPP Rennes)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
Tel-Aviv Sourasky Medical CenterCompletedPlasma Cell Myeloma | Myeloma-Multiple | Myeloma Multiple | Myeloma, Plasma-CellIsrael
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
National Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedRefractory Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma | DS (Durie/Salmon) Stage I Plasma Cell MyelomaUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on blood and bone marrow samples
-
Institut Claudius RegaudRecruiting
-
Assiut UniversityCompleted
-
Central Hospital, Nancy, FranceCompletedWaldenström MacroglobulinemiaFrance
-
Rigshospitalet, DenmarkZealand University Hospital; Herlev Hospital; Fonden til Lægevidenskabens Fremme and other collaboratorsCompletedMultiple MyelomaDenmark
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruitingT-lymphoblastic Lymphoma | T Acute Lymphoblastic Leukemia | Early T Acute Lymphoblastic Leukemia | Etp AllItaly
-
Hospices Civils de LyonJanssen, LPCompleted
-
Aalborg University HospitalOdense University Hospital; University of Southern DenmarkRecruitingMitochondrial Diseases | Bone Remodeling DisorderDenmark
-
Centre Hospitalier Universitaire, AmiensCompleted
-
Institut de cancérologie Strasbourg EuropeHôpitaux Universitaires de Strasbourg; GENTYANE (GEnoTYpage and sequencing...Completed
-
Assistance Publique - Hôpitaux de ParisCompletedGaucher DiseaseFrance